Xspray Pharma AB (DE:6XP)
FRANKFURT:6XP
6XP Stock Chart & Stats
€2.80
-€0.66(-17.25%)
At close: 4:00 PM EST
€2.80
-€0.66(-17.25%)
Day’s Range― - ―
52-Week Range€2.01 - €5.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€124.72M
Enterprise Value€1.26B
Total Cash (Recent Filing)€153.75M
Total Debt (Recent Filing)€170.11M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding45,916,573
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.07
Revenue Forecast (FY)€14.40M
Bulls Say, Bears Say
Bulls Say
Proprietary HyNap Formulation TechnologyXspray’s HyNap amorphous-nanoparticle formulation is a durable technological asset that can improve bioavailability and enable differentiated dosage forms. That platform creates sustainable competitive advantage for reformulating known drugs versus generic incumbents.
Licensing / Partnership-focused Business ModelA licensing-and-partnership model concentrates value capture through upfronts, development/regulatory milestones and royalties. This reduces commercialization capital needs, allows scale via partner networks, and can create recurring revenue streams once approvals occur.
Sizable Equity Base Provides Financial CushionA substantial equity base relative to assets gives the company balance-sheet flexibility to fund ongoing development and absorb near-term losses. This cushion lowers immediate solvency risk and supports the ability to pursue partnerships or raise capital on better terms.
Bears Say
No Commercial Revenue (pre-commercial)The company remains pre-commercial with no product sales from 2020–2025, meaning sustainable cash generation depends on future approvals or partner deals. This structural revenue absence prolongs reliance on external funding and delays path to profitability.
Deep And Worsening Cash BurnOperating cash flow deteriorated materially to -193.2M in 2025 and free cash flow remained deeply negative, indicating persistent cash burn. This structural outflow requires ongoing financing, risks dilution or restrictive covenants, and constrains investment flexibility.
Rapidly Rising Debt And Higher LeverageDebt increased sharply over recent years, raising leverage and fixed obligations. Higher indebtedness increases refinancing and interest-rate risk, reduces strategic optionality, and amplifies financial strain if clinical or commercial milestones are delayed.
Xspray Pharma AB News
6XP FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was €2.01 and its highest was €5.63 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is €124.72M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is May 06, 2026 which is in 34 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Feb 12, 2026. The company reported -€0.081 earnings per share for the quarter, missing the consensus estimate of €0.156 by -€0.237.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 45,916,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -€0.081 in its last earnings report, missing expectations of €0.156. Following the earnings report the stock price went up 4.846%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in DE:6XP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---